Biogen and Sage get August PDUFA date for oral depression drug
Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress | Business Wire
Biogen and Sage Therapeutics Share Update on FDA Advisory Committee for Zuranolone | Biogen
Sage Therapeutics Archives - Drug Discovery and Development
Biogen Bets Big To Bag Sage Depression And Tremor Drugs :: Scrip
Biogen, Sage prep 2022 filing for depression drug zuranolone | pharmaphorum
Neurology Drug Study Does Little for Sage Therapeutics, or Its Partner Biogen | Barron's
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Sage, Biogen's tremor drug hits goal, but 38% of people drop out | Fierce Biotech
NDA for Biogen-Sage's Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development - GeneOnline News
Biogen, Sage Therapeutics sign $3.1 psychiatric drug deal - Boston Business Journal
Sage/Biogen Announce Positive Results in Ph. 3 CORAL Depression Drug Trial
Sage-Biogen drug improves symptoms in postpartum depression study, Health News, ET HealthWorld
Neurologie : Biogen s'allie à Sage Therapeutics
Biogen Bets $1.5 Billion on Sage Therapeutics' Drug for Depressive Disorders | BioSpace
Sage and Biogen File NDA for Fast-Acting Postpartum Depression Drug – ISPE Boston
Biogen og Sage færdiggør løbende ansøgning til FDA for depressionsmiddel — MedWatch
Sage-Biogen drug improves symptoms in postpartum depression study | Reuters
Biogen Gives Sage Therapeutics $1.5 Billion In Deal To Develop Depression And Tremor Treatments | The Healthcare Technology Report.
Sage Therapeutics slumps, Biogen bounces
Should You Buy Sage Stock After the Biogen Investment? | The Motley Fool
Biogen, Sage plot 2022 filing for zuranolone approval, furthering turnaround of depression drug | Fierce Biotech
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Biogen
Biogen signs $1.5bn depression drug deal with Sage Therapeutics
